Trastuzumab is a recombinant humanized monoclonal antibody against the extracellular domain of epidermal growth factor receptor-2 (HER2) and is currently approved for the treatment of both metastatic and early-stage breast cancer as well as gastric cancer overexpressing HER2 2. This evidence concerns the gene ERBB2 and breast carcinoma.